These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 37261000)

  • 1. Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications.
    Anders HJ; Li Q; Steiger S
    Clin Kidney J; 2023 Jun; 16(6):928-938. PubMed ID: 37261000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].
    Butković M
    Acta Med Croatica; 2016 Dec; 70(4-5):233-9. PubMed ID: 29087102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
    Nishizawa H; Maeda N; Shimomura I
    Hypertens Res; 2022 Apr; 45(4):635-640. PubMed ID: 35046512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid and chronic kidney disease: which is chasing which?
    Johnson RJ; Nakagawa T; Jalal D; Sánchez-Lozada LG; Kang DH; Ritz E
    Nephrol Dial Transplant; 2013 Sep; 28(9):2221-8. PubMed ID: 23543594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
    Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
    Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease.
    Sellmayr M; Hernandez Petzsche MR; Ma Q; Krüger N; Liapis H; Brink A; Lenz B; Angelotti ML; Gnemmi V; Kuppe C; Kim H; Bindels EMJ; Tajti F; Saez-Rodriguez J; Lech M; Kramann R; Romagnani P; Anders HJ; Steiger S
    J Am Soc Nephrol; 2020 Dec; 31(12):2773-2792. PubMed ID: 32938648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological urate-lowering approaches in chronic kidney disease.
    Li X; Liu J; Ma L; Fu P
    Eur J Med Chem; 2019 Mar; 166():186-196. PubMed ID: 30769179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review.
    Vinik O; Wechalekar MD; Falzon L; Buchbinder R; van der Heijde DM; Bombardier C
    J Rheumatol Suppl; 2014 Sep; 92():70-4. PubMed ID: 25180131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
    BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update of genetics, co-morbidities and management of hyperuricaemia.
    Zhu C; Sun B; Zhang B; Zhou Z
    Clin Exp Pharmacol Physiol; 2021 Oct; 48(10):1305-1316. PubMed ID: 34133780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
    Stamp L; Dalbeth N
    Semin Arthritis Rheum; 2017 Feb; 46(4):457-464. PubMed ID: 27591828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current opinions on gout, its diagnosis and treatment].
    Němec P
    Vnitr Lek; 2012 Dec; 58(12):928-37. PubMed ID: 23427951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving cardiovascular and renal outcomes in gout: what should we target?
    Richette P; Perez-Ruiz F; Doherty M; Jansen TL; Nuki G; Pascual E; Punzi L; So AK; Bardin T
    Nat Rev Rheumatol; 2014 Nov; 10(11):654-61. PubMed ID: 25136785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
    Mei Y; Dong B; Geng Z; Xu L
    Front Endocrinol (Lausanne); 2022; 13():911968. PubMed ID: 35909538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
    Uchida S; Kumagai T; Chang WX; Tamura Y; Shibata S
    Contrib Nephrol; 2018; 192():56-68. PubMed ID: 29393121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
    Sampson AL; Singer RF; Walters GD
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009460. PubMed ID: 29084343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.